Site icon Impactiviti

Impactiviti Daily 022210

TODAY’S NEWS

Big news for Novartis on two fronts – Novartis has received a couple of pieces of good news from regulators in the USA this morning who have approved its meningococcal vaccine Menveo and granted a priority review for the Swiss major’s investigational oral treatment for multiple sclerosis fingolimod…more

Avandia – the bad news just won’t quit. The heart attack factor, and the when-did-they-not-share-what-info questions. And a call to just pull it from the market. A rough patch for GSK.

BI gets FDA approval for new Extended Release version of Mirapex (for Parkinson’s)

RECOMMENDED

Specialty sales training – For specialty sales forces (including oncology), you need specialized expertise. We have lots of it, in our Impactiviti Partner network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for vendor recommendations.

PLUS

From Wendy Blackburn: 7 things I Learned at the ePharma Summit. And, from Betsy Raymond StevensonCuring Pharma. Restoring the industry’s reputation will mean a lot of hard work, not just a PR campaign.

JUST FOR FUN

Time-killer: Top 10 Time-lapse Videos showing Nature at Work.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Exit mobile version